medicationPrescription only (US)Mirtazapine is FDA-approved for major depressive disorder in adultsThe cited network meta-analyses pool results across many individual trials rather than reporting a single dedicated mirtazapine RCT, so the numbers above reflect aggregated randomized evidence rather than one study
MirtazapineBenefits, Dosage & Interactions
Also known as: Remeron
Mirtazapine belongs to the NaSSA class — noradrenergic and specific serotonergic antidepressants — and is often grouped as a tetracyclic antidepressant. It is not an SSRI. It is typically taken in the evening. The reported plasma half-life is about 20 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 0 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
0 human randomized trials and regulatory approval on file.
Quick answer
Mirtazapine belongs to the NaSSA class — noradrenergic and specific serotonergic antidepressants — and is often grouped as a tetracyclic antidepressant. It is not an SSRI. Instead of blocking reuptake, it antagonises presynaptic alpha-2 autoreceptors to increase norepinephrine and serotonin release, while blocking 5-HT2, 5-HT3 and H1 receptors. That receptor profile is why it sedates strongly, increases appetite, and rarely causes the sexual side effects or nausea typical of SSRIs.
- Drug class
- NaSSA — noradrenergic and specific serotonergic antidepressant
- Also classified as
- Tetracyclic antidepressant (TeCA)
- Brand name
- Remeron
- Key receptor actions
- Alpha-2 antagonist; 5-HT2, 5-HT3 and H1 blocker
- Signature effects
- Sedation, increased appetite and weight gain
- Half-life
- Roughly 20–40 hours — once daily, usually at night
Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.
Plasma half-life
20–40 h
Typical timing
bedtime
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Trials pooled in these network meta-analyses used mirtazapine at daily doses generally between 15 mg and 45 mg for major depressive disorder[1][2][3]
Reported for Mirtazapine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Mirtazapine entry is written from. Each number matches an inline marker above.
- [1]Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysisCipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y · The Lancet · 2018 · Peer-reviewed · PMID 29477251
- [2]Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysisKishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y · Molecular Psychiatry · 2023 · Peer-reviewed · PMID 36253442
- [3]Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trialsHayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A · Journal of Affective Disorders · 2015 · Peer-reviewed · PMID 25911132
How to track Mirtazapine doses
Tracking Mirtazapine well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Mirtazapine with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is bedtime. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Mirtazapine through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 20 h, effects and timing shifts show up over days rather than instantly. Review Mirtazapine alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Mirtazapine dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Mirtazapine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Mirtazapine is an antidepressant medication approved by the U.S. Food and Drug Administration (FDA) primarily for the treatment of major depressive disorder. It is also sometimes used off-label for other conditions like anxiety disorders, insomnia, and nausea, though these uses are not FDA-approved for mirtazapine. It belongs to a class of antidepressants known as noradrenergic and specific serotonergic antidepressants (NaSSAs).
Mirtazapine is available in tablet form and orally disintegrating tablets. It is typically taken once daily, often at bedtime due to its sedative effects, and can be taken with or without food. The brand name for mirtazapine is Remeron.
As with all antidepressant medications, the full therapeutic effects of mirtazapine may not be immediately apparent, often requiring several weeks of consistent use to achieve optimal symptom improvement. It is crucial to continue taking the medication as prescribed and to not discontinue it abruptly without consulting a healthcare professional.
What does the research say about Mirtazapine?
Tap a section to expand.
Mirtazapine's primary mechanism of action involves enhancing noradrenergic and serotonergic neurotransmission in the central nervous system. Unlike many other antidepressants that directly inhibit the reuptake of neurotransmitters, mirtazapine acts as an antagonist at several receptors.
Specifically, it works by blocking alpha-2 adrenergic autoreceptors and heteroreceptors. This blockade disinhibits the release of norepinephrine and serotonin. By blocking presynaptic alpha-2 adrenergic autoreceptors, mirtazapine increases the release of norepinephrine. These alpha-2 heteroreceptors are also located on serotonergic neurons, meaning their blockade also increases serotonin release.
Furthermore, mirtazapine is a potent antagonist at serotonin 5-HT2 and 5-HT3 receptors. This antagonism is believed to contribute to its antidepressant and anxiolytic effects by preventing serotonin from binding to receptors associated with anxiety, insomnia, and gastrointestinal side effects. Instead, serotonin is preferentially available to bind to 5-HT1A receptors, which are thought to mediate the therapeutic effects of serotonin.
Mirtazapine also exhibits strong antagonism at histamine H1 receptors, which accounts for its sedating properties, particularly at lower doses. It has relatively weak alpha-1 adrenergic receptor blockade and minimal affinity for muscarinic cholinergic receptors, distinguishing its side effect profile from some other antidepressants (as described by DrugBank and FDA prescribing information).
Source for this section: Sources for How does Mirtazapine work?: Jumps to this entry in the sources and references list at the end of the page.
The primary established benefit of mirtazapine, supported by robust clinical trials and FDA approval, is the treatment of major depressive disorder. For individuals with depression, mirtazapine can help alleviate symptoms such as depressed mood, loss of interest or pleasure, changes in appetite or weight, sleep disturbances, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and suicidal ideation.
Some specific benefits observed with mirtazapine, particularly when compared to other antidepressants, include:
* **Improvement in Sleep:** Due to its potent histamine H1 receptor antagonism, mirtazapine often improves sleep quality and reduces insomnia, which can be a significant symptom of depression (data from clinical trials cited by FDA label).
* **Appetite Stimulation and Weight Gain:** For individuals with depression experiencing significant appetite loss and weight loss, mirtazapine's effect on appetite can be beneficial, leading to increased food intake and weight stabilization (as noted in MedlinePlus and FDA prescribing information).
* **Faster Onset of Action:** Some studies suggest that mirtazapine may have a relatively faster onset of antidepressant action compared to selective serotonin reuptake inhibitors (SSRIs), though this can vary highly among individuals (research referenced by PubChem).
* **Reduced Sexual Dysfunction:** Mirtazapine is less commonly associated with sexual side effects compared to SSRIs, which can be a significant advantage for some patients (information from Cochrane reviews).
While not FDA-approved, mirtazapine is sometimes used off-label to manage generalized anxiety disorder, panic disorder, and as a treatment for nausea and vomiting, particularly anticipatory nausea and vomiting due to its antiemetic properties stemming from 5-HT3 receptor antagonism (Examine.com). However, these uses are based on clinical experience and smaller studies, rather than large-scale, FDA-approved efficacy trials.
The efficacy of mirtazapine for the treatment of major depressive disorder is well-established through multiple randomized, double-blind, placebo-controlled clinical trials, which led to its FDA approval. These studies consistently demonstrated that mirtazapine significantly reduced depressive symptoms compared to placebo. For example, a meta-analysis of studies comparing various antidepressants, including mirtazapine, found it to be effective in ameliorating depressive symptoms across different populations (evidence cited by Mayo Clinic).
Clinical trials have also compared mirtazapine with other antidepressant classes, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Some research, including Cochrane reviews, suggests that mirtazapine may have a comparable or potentially superior efficacy profile to some SSRIs for certain patient groups, particularly those with prominent insomnia and anxiety symptoms alongside depression. However, direct comparisons often highlight differences in side effect profiles rather than vast differences in overall efficacy for depression across all patients (as summarized by NIH ODS).
Studies investigating its use for generalized anxiety disorder, while promising, are generally smaller and less conclusive than those for major depressive disorder. Its antiemetic effects by 5-HT3 receptor antagonism have been explored in various settings, including chemotherapy-induced nausea and vomiting, with some positive but not universally applicable results (research detailed by PubChem). The evidence for these off-label uses is not as extensive or definitive as for its primary indication.
Mirtazapine, like all medications, can cause side effects. Many side effects are mild and may diminish over time as the body adjusts to the medication. Common side effects often include:
* Drowsiness or sedation, especially during initial treatment and more pronounced at lower doses.
* Increased appetite and weight gain.
* Dry mouth.
* Constipation.
* Dizziness.
* Fatigue.
Less common but more serious side effects can also occur and require immediate medical attention. These include:
* Serotonin syndrome: Symptoms may include agitation, hallucinations, rapid heartbeat, fever, sweating, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea. This risk increases when mirtazapine is taken with other serotonergic drugs (detailed in FDA label).
* Agranulocytosis or severe neutropenia: This is a rare but serious blood disorder (very low white blood cell count) that can increase the risk of infection. Symptoms can include fever, chills, sore throat, or other signs of infection (FDA warnings).
* Angle-closure glaucoma: Individuals with pre-existing untreated narrow angles may be at risk.
* Hypotension (low blood pressure), including orthostatic hypotension (a drop in blood pressure upon standing, leading to dizziness).
* Mania or hypomania: Can occur in individuals with undiagnosed bipolar disorder.
* Suicidal thoughts or actions: This is a known risk with antidepressants, particularly in young adults and adolescents, especially at the beginning of treatment or when the dose is changed (black box warning from FDA).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several important warnings are associated with mirtazapine use. Patients and caregivers should be aware of these potential risks:
* **Suicidality Risk:** Antidepressants, including mirtazapine, carry a black box warning from the FDA regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) compared to placebo. Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is required, especially during the initial treatment period or at times of dose adjustment. Families and caregivers should be vigilant for emerging or worsening depression, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania.
* **Serotonin Syndrome:** The risk of serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions increases when mirtazapine is co-administered with other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's wort) or drugs that impair serotonin metabolism (e.g., MAOIs). Symptoms can be life-threatening and include changes in mental status, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms.
* **Agranulocytosis:** Mirtazapine has been associated with very rare cases of agranulocytosis (severe decrease in white blood cells). If a patient develops an infection, fever, sore throat, or other flu-like symptoms during treatment, a complete blood count should be performed.
* **Weight Gain and Metabolic Changes:** Significant weight gain has been reported with mirtazapine, which can be linked to other metabolic changes such as increased cholesterol and triglycerides. Patients should be monitored for these effects, particularly those with pre-existing metabolic conditions (information from Mayo Clinic and FDA label).
* **Mania/Hypomania Activation:** In patients with bipolar disorder, mirtazapine has the potential to precipitate a mixed/manic episode. It should be used with caution in patients with a history of mania or hypomania.
* **Angle-Closure Glaucoma:** The pupil-dilating effect of mirtazapine can trigger an angle-closure attack in patients with anatomically narrow angles that have not undergone iridectomy.
* **Discontinuation Syndrome:** Abrupt discontinuation of mirtazapine, especially after prolonged use, can lead to withdrawal-like symptoms, including dizziness, abnormal dreams, sensory disturbances (e.g., paresthesias), agitation, anxiety, nausea, and vomiting. Dosing should be tapered gradually under medical supervision.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Mirtazapine is contraindicated in certain situations due to potential serious adverse reactions:
* **Concomitant use or within 14 days of discontinuing monoamine oxidase inhibitors (MAOIs):** This combination significantly increases the risk of serotonin syndrome, which can be life-threatening. Similarly, mirtazapine should not be started within 14 days of discontinuing an MAOI (FDA prescribing information).
* **Known hypersensitivity to mirtazapine or any excipients in the formulation:** Symptoms could include rash, hives, swelling, or difficulty breathing, indicating a severe allergic reaction (DrugBank).
Other conditions require careful consideration and close monitoring rather than absolute contraindication:
* **Severe renal or hepatic impairment:** Mirtazapine clearance may be reduced, necessitating dose adjustments (EMA SmPC).
* **History of seizures or conditions predisposing to seizures (e.g., brain damage, alcoholism):** Mirtazapine can lower the seizure threshold; use with caution (PubChem).
* **Cardiovascular disease (e.g., angina pectoris, recent myocardial infarction, heart failure):** While not an absolute contraindication, caution is advised due to potential for orthostatic hypotension.
* **Diabetes mellitus:** Mirtazapine can affect glycemic control. Patients with diabetes should monitor blood glucose levels closely (MedlinePlus).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Mixing mirtazapine with certain other medications or substances can lead to dangerous interactions. The most critical combinations to avoid or use with extreme caution include:
* **Monoamine Oxidase Inhibitors (MAOIs):** This includes medications like isocarboxazid, phenelzine, selegiline, and tranylcypromine, as well as linezolid (an antibiotic) and methylene blue (an injectable dye). Combining mirtazapine with MAOIs or using them within a 14-day window of each other is contraindicated due to the high risk of severe, potentially fatal serotonin syndrome (FDA label).
* **Other Serotonergic Drugs:** Co-administration with other medications that increase serotonin levels can greatly elevate the risk of serotonin syndrome. This includes, but is not limited to, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), triptans (for migraines), fentanyl, lithium, tramadol, buspirone, amphetamines, and the herbal supplement St. John's Wort. Careful monitoring is essential if these combinations are deemed necessary by a clinician (Mayo Clinic).
* **Central Nervous System (CNS) Depressants:** Mirtazapine itself causes sedation. Combining it with other CNS depressants, such as benzodiazepines (e.g., alprazolam, lorazepam), other sedating antidepressants, antipsychotics, muscle relaxants, opioid pain medications, or alcohol, can significantly enhance sedative effects, leading to excessive drowsiness, dizziness, impaired coordination, and potentially dangerous respiratory depression (DrugBank).
* **Drugs Metabolized by CYP2D6 and CYP3A4:** Mirtazapine is metabolized by several liver enzymes, including CYP2D6 and CYP3A4. Strong inhibitors of these enzymes (e.g., ketoconazole, erythromycin, cimetidine, HIV protease inhibitors, nefazodone, fluvoxamine) can increase mirtazapine levels, potentially enhancing its effects and side effects. Conversely, strong inducers (e.g., carbamazepine, phenytoin, rifampicin) can decrease mirtazapine levels, reducing its effectiveness (PubChem).
* **Warfarin:** Although interactions are generally minor, there have been rare reports of increased INR and prothrombin time with concomitant use of mirtazapine and warfarin. Patients on anticoagulants should have their coagulation parameters monitored (EMA SmPC).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Mirtazapine is typically taken once daily, usually in the evening or at bedtime. This timing is often chosen due to the common side effect of drowsiness or sedation associated with the medication.
The half-life of mirtazapine is approximately 20 to 40 hours, with a mean of 30 hours, meaning it stays in the body for an extended period. This long half-life allows for once-daily dosing. Taking it at bedtime helps to mitigate the sedative effects and may improve sleep in individuals experiencing insomnia as a symptom of their condition.
Mirtazapine can be taken with or without food. However, taking it with food may help to reduce any potential stomach upset in sensitive individuals. Consistent daily timing is generally recommended to maintain stable drug levels in the body and optimize therapeutic effects (information from FDA prescribing information and MedlinePlus).
Source for this section: Sources for When should you take Mirtazapine?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Mirtazapine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
| Melatonin | Note | Compound pairConfidence: theoretical | Additive sedation possible.Source pending | Start at low melatonin dose (0.3–1 mg) when combined with prescription sedatives. |
Frequently asked questions about Mirtazapine
Mirtazapine is a medication. It is also known as Remeron. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
Mirtazapine is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Mirtazapine, it is typically taken in the evening and its approximate half-life is 20 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Mirtazapine carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for Mirtazapine comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Mirtazapine is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 20 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Mirtazapine with no sign-up.
There is no single answer for Mirtazapine plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Mirtazapine with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 20 hours, once-daily dosing is the usual pattern for Mirtazapine. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 20 hours, a single missed dose of Mirtazapine usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Mirtazapine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
No. SSRIs block the serotonin transporter; mirtazapine instead blocks presynaptic alpha-2 autoreceptors and several postsynaptic serotonin receptors. This is why it is often chosen when SSRIs have failed or when their nausea and sexual side effects are intolerable. This is educational information, not medical advice.
At low doses the potent H1 antihistamine effect dominates, producing strong sedation. As the dose rises, noradrenergic activity increases and partly offsets that antihistamine sedation — which is the widely described clinical paradox of the drug. This is educational information, not medical advice.
Blockade of H1 and 5-HT2C receptors both increase appetite, and labeling lists increased appetite and weight gain among the most common effects. In some settings — older adults with poor appetite, or depression with weight loss — this is the reason it is chosen. This is educational information, not medical advice.
Combining them is a recognized strategy in treatment-resistant depression, sometimes called "California rocket fuel" when paired with venlafaxine, but it raises serotonin syndrome risk and must be prescriber-directed with monitoring. This is educational information, not medical advice.
Which studies looked at Mirtazapine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Clinical pharmacokinetics of mirtazapine.(opens PubMed in a new tab)Clinical pharmacokinetics · 2000 · PMID 10885584 · https://pubmed.ncbi.nlm.nih.gov/10885584/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 46782643(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/46782643
Verify at
Publisher search links for Mirtazapine. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Mirtazapine?
Plain-text summary, safe to quote verbatim:
Mirtazapine belongs to the NaSSA class - noradrenergic and specific serotonergic antidepressants - and is often grouped as a tetracyclic antidepressant. It is not an SSRI. It is typically taken in the evening. The reported plasma half-life is about 20 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/mirtazapine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Mirtazapine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/mirtazapine
What compounds are similar to Mirtazapine?
Others in the medication category or studied for the same goals.